Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome by Chapman, Andrew et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Novel high-sensitivity cardiac troponin I assay in patients with
suspected acute coronary syndrome
Citation for published version:
Chapman, A, Fujisawa, T, Lee, KK, Andrews, J, Anand, A, Sandeman, D, Ferry, AV, Stewart, S, Marshall,
L, Strachan, F, Gray, A, Newby, D, Shah, A & Mills, N 2018, 'Novel high-sensitivity cardiac troponin I assay
in patients with suspected acute coronary syndrome' Heart. DOI: 10.1136/heartjnl-2018-314093
Digital Object Identifier (DOI):
10.1136/heartjnl-2018-314093
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Heart
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
  1Chapman AR, et al. Heart 2018;0:1–7. doi:10.1136/heartjnl-2018-314093
Original research article
Novel high-sensitivity cardiac troponin I assay in 
patients with suspected acute coronary syndrome
andrew r chapman,1 takeshi Fujisawa,1 Kuan Ken lee,1 Jack Patrick andrews,1 
atul anand,1 Dennis sandeman,1 amy V Ferry,1 stacey stewart,1 lucy Marshall,1 
Fiona e strachan,1 alasdair gray,2,3 David e newby,1 anoop s V shah,1 
nicholas l Mills1,4 
Coronary artery disease
To cite: chapman ar, 
Fujisawa t, lee KK, et al. 
Heart epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
heartjnl-2018-314093
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2018- 314093).
1BhF centre for cardiovascular 
science, University of edinburgh, 
edinburgh, UK
2Department of emergency 
Medicine, royal infirmary of 
edinburgh, edinburgh, UK
3eMerge research group, 
royal infirmary of edinburgh, 
edinburgh, UK
4Usher institute of Population 
health sciences and informatics, 
University of edinburgh, 
edinburgh, UK
Correspondence to
Dr andrew r chapman, BhF 
centre for cardiovascular 
science, University of edinburgh, 
edinburgh eh16 4sB, UK;  a. r. 
chapman@ ed. ac. uk
received 30 august 2018
revised 13 October 2018
accepted 17 October 2018
© author(s) (or their 
employer(s)) 2018. re-use 
permitted under cc BY. 
Published by BMJ.
AbsTrACT
background high-sensitivity cardiac troponin assays 
enable the early risk stratification of patients with 
suspected acute coronary syndrome to identify those at 
low risk of myocardial infarction or cardiac death. We 
evaluated the performance of a novel high-sensitivity 
cardiac troponin i assay in early rule out pathways.
Methods in 1920 patients with suspected acute 
coronary syndrome, cardiac troponin was measured 
using the siemens atellica high-sensitivity cardiac 
troponin i assay (99th centile: 34 ng/l women, 53 ng/l 
men). We evaluated three pathways which use either 
low risk-stratification thresholds of cardiac troponin 
(High-SensitivityTroponin in the Evaluation of patients 
with Acute Coronary Syndrome (high-steacs) and the 
european society of cardiology (esc) 1 hour pathway) 
or the 99th centile diagnostic threshold (esc 3 hour 
pathway) to rule out myocardial infarction.
results the primary outcome of myocardial infarction 
or cardiac death at 30 days occurred in 14.4% 
(277/1920). the high-steacs pathway ruled out 63% 
of patients (1218/1920), with five missed events for a 
negative predictive value (nPV) of 99.5% (95% ci (ci) 
99.1% to 99.8%). similar performance was observed for 
the esc 1 hour pathway with an nPV of 99.0% (97.6% 
to 99.8%). in contrast, the esc 3 hour pathway ruled out 
65% of patients (1248/1920), but missed 25 events for 
an nPV of 98.0% (97.1% to 98.7%).
Conclusions a novel high-sensitivity cardiac troponin 
i assay can safely identify patients at low risk of 
myocardial infarction or cardiac death. Diagnostic 
pathways that use low cardiac troponin concentrations 
for risk stratification miss fewer events than those that 
rely on the 99th centile to rule out myocardial infarction.
Trial registration nct1852123.
InTroduCTIon
High-sensitivity assays enable quantification of 
low concentrations of cardiac troponin in healthy 
men and women, and permit accurate identifica-
tion of the normal reference range and the 99th 
centile threshold recommended for the diag-
nosis of myocardial infarction.1 In addition to 
improvements in diagnostic accuracy, high-sen-
sitivity cardiac troponin assays have the potential 
to improve the efficiency and safety of healthcare 
delivery by improving early risk stratification in 
patients with suspected acute coronary syndrome.
In a meta-analysis of 22 457 patients with 
suspected acute coronary syndrome, a high-sen-
sitivity cardiac troponin I concentration <5 ng/L 
identified half of all patients as low risk with a 
negative predictive value (NPV) of 99.5% for 
myocardial infarction or cardiac death at 30 days.2 
The High-Sensitivity Troponin in the  Evaluation of 
patients  with  A cute  Coronary  Syndrome (High-
STEACS) pathway incorporates this threshold 
at presentation with serial testing at 3 hours and 
misses less than one event in every 200 patients 
tested.3 The European Society of Cardiology (ESC) 
recommend a similar 1 hour pathway, which applies 
assay specific risk stratification thresholds and 
has excellent diagnostic performance.4–6 The ESC 
3 hour pathway uses the 99th centile to rule in and 
rule out myocardial infarction, but the safety of this 
pathway has been challenged.3 7
Many early rule out pathways use assay specific 
thresholds, which has limited wider implemen-
tation of these promising approaches in practice. 
Here, we evaluate the diagnostic performance of 
a novel high-sensitivity cardiac troponin I assay 
(Atellica IM high-sensitivity troponin I, Siemens 
Healthineers) across three established risk stratifi-
cation pathways currently used in clinical practice.
MeThods
study population
Patients with suspected acute coronary syndrome 
were recruited from the Emergency Department 
of the Royal Infirmary of Edinburgh, a tertiary 
care hospital in Scotland, between 1 June 2013 
and 31 March 2017 into a substudy of the High-
STEACS trial. All patients in whom the attending 
clinician requested cardiac troponin for suspected 
acute coronary syndrome were eligible. We did not 
enrol patients with ST-segment elevation myocar-
dial infarction, those unable to provide consent or 
those from outside our region to ensure complete 
follow-up. Blood samples were obtained at presen-
tation and at 6–12 hours as part of routine clin-
ical care, with surplus serum or lithium-heparin 
plasma samples collected. Patients provided written 
informed consent for additional sampling at 1 or 
3 hours (supplementary table S1). Samples were 
centrifuged, aliquoted and stored at −80°C for 
batch processing. 
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high-sensitivity cardiac troponin I assay
The Siemens Atellica IM High Sensitivity Troponin I assay 
(Siemens Healthineers) is a three-site sandwich immunoassay 
with a limit of detection of 1.6 ng/L and limit of quantification of 
2.5 ng/L. The upper reference limit 99th centile was determined 
in 2007 samples from healthy individuals as 34 ng/L in women, 
and 53 ng/L in men, with a single threshold of 45 ng/L. In the 
reference range population, 75% of patients had values greater 
than the limit of detection. All measurements were undertaken 
by Siemens Healthineers at a central laboratory, who were 
blinded to all clinical information with results provided to the 
research team and linked to the trial database for analysis.
baseline characteristics
Patient characteristics, clinical observations and cardiac investi-
gations were obtained from a dedicated case record form, patient 
questionnaire and the electronic patient record.
diagnostic adjudication
The final diagnosis was adjudicated by two independent cardi-
ologists, with consensus from a third cardiologist where there 
was discrepancy following review of all clinical information, 
investigations and outcomes from presentation to 30 days 
(supplementary appendix). Any high-sensitivity cardiac troponin 
I concentration above the sex-specific 99th centile upper refer-
ence limit (Siemens Healthineers Atellica TnIH; 34 ng/L for 
women, 53 ng/L for men) was considered evidence of myocar-
dial necrosis. Patients were classified as having type 1 myocar-
dial infarction, type 2 myocardial infarction or myocardial injury 
in accordance with the third universal definition of myocardial 
infarction as reported previously.5 8
Clinical outcomes
The primary outcome was a composite of index type 1 myocar-
dial infarction or type 1 myocardial infarction or cardiac death at 
30 days. We used regional and national registries in addition to 
individual patient follow-up at 30 days, as previously described.3 
All subsequent events were adjudicated using the same approach 
as for the index presentation. Cardiac death was defined as any 
death due to myocardial infarction, arrhythmia or heart failure.3
Clinical pathways
We evaluated the safety and efficacy of the High-STEACS 
pathway, the ESC 1 hour and the ESC 3 hour pathways.3 5 We 
determined diagnostic performance to rule out a composite 
outcome of index type 1 myocardial infarction, and type 1 
myocardial infarction or cardiac death at 30 days.
high-sTeACs pathway
The derivation and validation of the High-STEACS pathway was 
undertaken using the Abbott ARCHITECTSTAT high-sensitivity 
cardiac troponin I assay,3 8 with the same thresholds applied 
to the Siemens Healthineers Atellica TnIH assay without reca-
libration. Patients without myocardial ischaemia on the ECG 
and cardiac troponin concentrations<5 ng/L at presentation 
were considered low risk, with myocardial infarction ruled out 
without further testing, unless they present early with symptom 
onset <2 hours from presentation where cardiac troponin 
was retested 3 hours after presentation. Patients with cardiac 
troponin concentrations≥5 ng/L at presentation were retested 
at 3 hours after presentation. Myocardial infarction was ruled 
out at 3 hours if cardiac troponin concentrations are unchanged 
(delta <3 ng/L) and remain ≤99th centile.
esC 1 hour pathway
For the ESC 1 hour pathway, in patients without ischaemia on 
the ECG, myocardial infarction was ruled out where cardiac 
troponin concentrations were <3 ng/L at presentation and symp-
toms were present for >3 hours. In all other patients, myocar-
dial infarction was ruled out if cardiac troponin concentrations 
were <6 ng/L at presentation with a change of <3 ng/L after 
1 hour. Patients were ruled in where there was myocardial isch-
aemia on the ECG, if troponin concentrations were ≥120 ng/L 
at presentation, or a change of ≥12 ng/L was observed at 1 hour. 
These thresholds were recently derived and validated using the 
Siemens ADVIA Centaur assay and did not feature in the original 
ESC guidelines.4
esC 3 hour pathway
For the ESC 3 hour pathway, myocardial infarction was ruled 
out in patients without ischaemia on the ECG where cardiac 
troponin concentrations were <99th centile at presenta-
tion in patients with symptoms for >6 hours. In patients with 
symptoms for <6 hours, a second troponin measurement was 
performed 3 hours from presentation, with myocardial infarc-
tion ruled out if cardiac troponin remains <99th centile or was 
>99th centile without a significant change in concentration.5 
Previously published guidance recommended use of a change 
in cardiac troponin concentration >50% of the 99th centile 
upper reference limit at 3 hours where the initial concentration 
was ≤99th centile, or >20% when the initial concentration 
was >99th centile. Patients were ruled out if pain free, and the 
GRACE score was <140.9 We calculated the GRACE score for in 
hospital death; this algorithm is available online.10
subgroup and sensitivity analyses
We evaluated the performance of all pathways in prespecified 
subgroups, by age (≤65 vs >65 years), sex, history of ischaemic 
heart disease and time from symptom onset to presentation (2, 3 
or 6 hours). As not all centres employ sex-specific thresholds, we 
repeated the primary analysis using a single diagnostic threshold 
(>45 ng/L). In a sensitivity analysis, we determined the perfor-
mance of all pathways for a composite outcome of any myocar-
dial injury (type 1 or type 2 myocardial infarction, or myocardial 
injury, or cardiac death at 30 days).
statistical analysis
Baseline characteristics are summarised as mean (SD) or median 
(IQR) as appropriate. The primary outcome was the NPV of each 
pathway for the composite outcome estimated used a Bayesian 
approach with a Jeffrey’s prior as this is more robust when CIs 
approach 0 or 1.11 We determined absolute (hs-TnI3hr – hs-TnI0hr) 
and relative ([(hs-TnI3hr – hs-TnI0hr)/hs-TnI0hr] x 100) change in 
cardiac troponin concentration from presentation to 3 hours, 
and determined sensitivity, specificity and positive predictive 
value (PPV) with 95% CIs using a Bayesian approach as per the 
NPV. We determined the number of patients ruled in or ruled 
out as a proportion of the analysis population. As the ESC 1 hour 
algorithm stratifies patients into an observation group, where 
patients are neither ruled in or ruled out, these patients are not 
included in calculations of NPV and sensitivity (rule out group), 
or PPV and specificity (rule in group). We report in accordance 
with the STARD criteria for diagnostic accuracy studies.12 All 
analyses were performed using R V. 3.2.2.
resulTs
We enrolled 1951 patients with suspected acute coronary 
syndrome, of whom 1920 had a cardiac troponin I result 
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available at presentation (table 1 and supplementary figure S1, 
respectively). The adjudicated diagnosis was type 1 myocardial 
infarction in 274 patients (14.3%), type 2 myocardial infarc-
tion in 64 patients (3.3%) and myocardial injury in 28 patients 
(1.5%), with six deaths from a cardiac cause at 30 days. Cardiac 
troponin concentrations were above the limit of detection in 
90.8% (1743/1920) of patients, and higher at presentation in 
patients with type 1 myocardial infarction compared with those 
without (150 ng/L, IQR 57–800 ng/L vs 4 ng/L, IQR 2–7 ng/L).
high-sTeACs pathway
The High-STEACS pathway identified 63.4% (1218/1920) of 
patients as low risk, with five missed events (four index type 1 
myocardial infarction and one type 1 myocardial infarction at 
30 days) for an NPV of 99.5% (95% CI 99.1% to 99.8%) and 
sensitivity of 98.0% (95% CI 96.4% to 99.5%). The PPV and 
specificity for the overall pathway were 38.8% (95% CI 35.2% 
to 42.4%) and 73.8% (95%CI 71.7% to 75.9%), respectively 
(figure 1).
esC 1 hour pathway
Where samples were available at presentation and 1 hour 
(406/1920; 21%), we evaluated performance of the ESC 1 hour 
rule out pathway. In this population, the prevalence of the 
primary outcome was 7.6% (31/406). The ESC 1 hour pathway 
identified 64.5% (262/406) of patients as low risk at 1 hour, 
with two missed cases, for an NPV of 99.0% (95% CI 97.6% 
to 99.8%) and sensitivity of 92.2% (95% CI 83% to 99.4%). 
The pathway identified 6.9% (28/406) of patients as high-risk 
for a PPV of 77.6% (95% CI 61.1% to 90.5%) and specificity of 
98.2% (95% CI 96.8% to 99.4%). There were 28.6% (116/406) 
of patients who did not meet the rule in or rule out criteria, and 
were placed in the observe group (figure 2).
Table 1 Baseline characteristics of the study population
All patients
(n=1920)
≤99th centile
(n=1620)
>99th centile
(n=300) P values
Baseline characteristics
  Age 61.5 (14.2) 60.3 (14.1) 67.7 (13.3) <0.001
  Male (%) 1174 (61.1) 975 (60.2) 199 (66.3) 0.052
  Chest pain (%) 1613 (84.3) 1369 (84.8) 244 (81.3) 0.389
  Symptom to arrival time (min) 199 (118–461.5) 199 (115–445) 199 (134–521) 0.044
Medical history
  Diabetes mellitus (%) 281 (14.6) 222 (13.7) 59 (19.7) 0.009
  Hypertension (%) 763 (39.7) 614 (37.9) 149 (49.7) <0.001
  Hyperlipidaemia (%) 760 (39.6) 630 (38.9) 130 (43.3) 0.167
  Family history (%) 922 (48.0) 782 (48.3) 140 (46.7) 0.654
  Ischaemic heart disease (%) 578 (30.1) 474 (29.3) 104 (34.7) 0.071
  Previous myocardial infarction (%) 455 (23.7) 361 (22.3) 94 (31.3) 0.001
  Previous percutaneous coronary intervention (%) 363 (18.9) 294 (18.1) 69 (23.0) 0.059
  Previous coronary artery bypass grafting (%) 117 (6.1) 88 (5.4) 29 (9.7) 0.007
  Previous heart failure (%) 64 (3.3) 46 (2.8) 18 (6.0) 0.009
  Previous stroke (%) 119 (6.2) 96 (5.9) 23 (7.7) 0.309
  Smoker (%) 385 (20.1) 327 (20.2) 58 (19.3) 0.581
Medication on admission
  Aspirin (%) 650 (33.9) 530 (32.7) 120 (40.0) 0.017
  Clopidogrel (%) 250 (13.0) 201 (12.4) 49 (16.3) 0.078
  Beta-blocker (%) 518 (27.0) 427 (26.4) 91 (30.3) 0.176
  ACE Inhibitor (%) 578 (30.1) 469 (29.0) 109 (36.3) 0.013
  Statin (%) 819 (42.7) 678 (41.9) 141 (47.0) 0.111
  Calcium channel blocker (%) 240 (12.5) 195 (12.0) 45 (15.0) 0.183
  Warfarin (%) 104 (5.4) 83 (5.1) 21 (7.0) 0.238
ECG findings
  ST depression (%) 112 (5.8) 62 (3.8) 50 (16.7) <0.001
  ST elevation (%) 58 (3.0) 40 (2.5) 18 (6.0) 0.002
  T-wave inversion (%) 298 (15.5) 213 (13.1) 85 (28.3) <0.001
Adjudicated index diagnosis
  Type 1 myocardial infarction (%) 274 (14.3) 54 (3.3) 220 (73.3) <0.001
  Type 2 myocardial infarction (%) 64 (3.3) 17 (1.0) 47 (15.7) <0.001
  Myocardial injury (%) 28 (1.5) 2 (0.1) 26 (8.7) <0.001
30-Day outcomes
  Type 1 myocardial infarction at 30 days (%)* 8 (0.4) 2 (0.1) 6 (2.0) <0.001
  Cardiac death at 30 days (%) 6 (0.3) 2 (0.1) 4 (1.3) 0.004
  Type 1 myocardial infarction or cardiac death at 30 days (%) 277 (14.4) 57 (3.5) 220 (73.3) <0.001
Troponin strata based on presentation concentration. Values are mean (SD), median (IQR) or n(%).
*Excluding index events.
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esC 3 hour pathway
The ESC 3 hour pathway identified 65% (1248/1920) of patients 
as low risk, with 25 missed events (24 index type 1 myocardial 
infarction and one cardiac death at 30 days) for an NPV of 98.0% 
(95% CI 97.1% to 98.7%) and sensitivity of 90.8% (87.4 to 
94.1%)%). The PPV and specificity for the overall pathway were 
37.5% (95% CI 33.9% to 41.2%) and 74.4% (95% CI 72.3% to 
76.5%), respectively (figure 3).
Prespecified subgroup analyses
We repeated the primary analysis in subgroups, stratified by age, 
gender, history of ischaemic heart disease and time of symptom 
onset. The performance of the High-STEACS pathway was 
robust in all groups (supplementary figure S2). The ESC 3 hour 
pathway (99th centile only) performed less well in patients with 
a history of ischaemic heart disease, where the NPV was 96.5% 
(95% CI 94.5% to 98%, supplementary figure S3). No signif-
icant heterogeneity was observed in the ESC 1 hour pathway 
(supplementary figure S4).
sensitivity analyses
We repeated all analyses using the recommended single diag-
nostic threshold of 45 ng/L and observed no variation in perfor-
mance (supplementary table S2). We then repeated all analyses 
using a composite endpoint including type 1 or type 2 myocardial 
infarction, myocardial injury or cardiac death, and we observed 
no changes in safety or efficacy (supplementary table S3).
dIsCussIon
In a prospective observational cohort study of patients with 
suspected acute coronary syndrome, we performed the first 
evaluation of a novel high-sensitivity cardiac troponin I assay 
in three commonly used rule out pathways, and make a number 
of observations. First, using this assay, cardiac troponin concen-
trations were measurable in >90% of patients. Second, when 
applied in pathways which use low concentrations of cardiac 
troponin for risk stratification, this assay reliably identified 
patients at low risk of myocardial infarction or cardiac death at 
30 days, with one missed case in every 200 patients tested. These 
Figure 1 Diagnostic performance of the High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS) 
pathway. NPV, negative predictive value; PPV, positive predictive value.
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findings were consistent by age, sex, history of ischaemic heart 
disease and time of symptom onset. Third, when applied in the 
ESC 3 hour pathway which rules out myocardial infarction at 
the 99th centile, there was a much higher risk of missed events, 
particularly in those with a history of ischaemic heart disease.
High-sensitivity cardiac troponin assays are defined by analyt-
ical characteristics which reflect their precision. The Interna-
tional Federation of Clinical Chemistry recommends the term 
high-sensitivity be reserved for an assay meeting two criteria; the 
coefficient of variation must be ≤10% at the 99th centile, and 
concentrations should be measurable (above the limit of detec-
tion) in at least 50% of a healthy reference population.13 14 At 
present, just one commercially available high-sensitivity cardiac 
troponin I assay meets these criteria (ARCHITECTSTAT, Abbott 
Diagnostics). The Siemens Healthineers Atellica TnIH assay does 
meet these criteria and provides an additional choice of cardiac 
troponin I assay to hospital specialists considering implementing 
an early rule out pathway in clinical practice.
We evaluated the performance of the Atellica assay across 
three commonly applied risk stratification pathways. The ESC 
3 hour pathway applies the 99th centile as the threshold both to 
rule in and rule out myocardial infarction in conjunction with 
the GRACE risk score. In this analysis, the NPV and sensitivity 
were low, at 98.0% and 90.1% respectively, below the perfor-
mance considered to be clinically acceptable in practice.15 This 
pathway was established at a time when contemporary troponin 
assays with higher diagnostic thresholds were used for diagnosis, 
and now, new approaches are required to match the precision 
offered by high-sensitivity troponin assays.
The High-STEACS and ESC 1 hour pathways performed well, 
with no heterogeneity observed by age, sex, history of ischaemic 
heart disease or time of symptom onset. While the thresholds 
applied in the High-STEACS pathway were derived and validated 
using the Abbott ARCHITECTSTAT high-sensitivity cardiac troponin 
I assay, they translate well to the Atellica TnIH assay with compa-
rable efficacy and safety. This is because the High-STEACS pathway 
is based on three basic principles that make it likely to perform 
well across all high-sensitivity assays without recalibration. First, 
low troponin concentrations at presentation identify those at low 
risk. The risk stratification threshold of <5 ng/L employed here 
has been validated for both troponin I and troponin T in >30 000 
patients.2 16 Second, increasing troponin concentrations above this 
Figure 2 Diagnostic performance of the European Society of Cardiology (ESC) 1 hour pathway. NPV, negative predictive value; PPV, positive 
predictive value.
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threshold may be important and require further investigation. We 
define this using a change in troponin concentration of ≥3 ng/L 
based on the lowest measurable change in concentration that 
exceeds the analytical variation of a high-sensitivity assay.17 Third, 
to ensure our pathway is consistent with international guidelines 
and easy to integrate into clinical practice, we use a sex-specific 
99th centile to identify patients who require admission for further 
investigation.18 We accept that this threshold is imperfect19 and 
assay specific, and therefore use the manufacturer’s recommended 
99th centile concentration. Similarly, the thresholds applied in the 
ESC 1 hour pathway were derived and validated using the Siemens 
ADVIA Centaur assay, but our results were consistent with this 
initial study, suggesting additional calibration is not required.4 20
For clinicians considering implementation of an early rule out 
pathway, using very low cardiac troponin concentrations to iden-
tify low-risk patients has major potential to improve safety and 
decision making in the emergency department. As both pathways 
incorporating risk stratification thresholds have demonstrated 
similar safety and efficacy in a number of studies, the choice of 
approach is best determined by clinicians and laboratory staff 
at a local level. Alternative approaches using clinically validated 
risk scores are possible, such as the History, ECG, Age, Risk 
Factors Troponin (HEART), Emergency Department Assess-
ment of Chest Pain Score (EDACS), Global Registry of Acute 
Coronary Events (GRACE) and Thrombolysis in Myocardial 
Infarction (TIMI) scores,21–24 but to date they have not shown 
benefit over pathways applying risk stratification thresholds.25 It 
is recognised that in some centres a 1 hour sample interval may 
be difficult to achieve, given the time taken for a sample to be 
obtained, transported to the laboratory, analysed and reported. 
However, while implementation of any pathway may require 
service redesign and investment in infrastructure, the potential 
improvements in efficiency by identifying two-thirds of patients 
as low risk in the emergency department are large and could lead 
to significant cost savings.
There are a number of limitations to this study which merit 
consideration. First, this was a single-centre observational cohort 
study, but as a tertiary cardiology centre with a large emergency 
department, we believe our findings are likely to be generalis-
able. Second, 1 hour samples for the evaluation of the ESC 1 hour 
pathway were only available in one in five patients, and in this 
population the prevalence of myocardial infarction or cardiac 
death was lower, indicating some selection bias and limiting the 
applicability of our findings. However, the observed performance 
is consistent with prior evaluations in other cohorts. Finally, no 
patients were managed on the basis of the measured cardiac 
troponin concentrations, and differences in clinical management 
and follow-up could have influenced outcomes. Two randomised 
controlled trials evaluating the implementation of risk stratifica-
tion pathways are currently under way; an evaluation of the ESC 
Figure 3 Diagnostic performance of the European Society of Cardiology (ESC) 3 hour pathway. NPV, negative predictive value; PPV, positive 
predictive value.
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1 hour algorithm (LoDED trial; ISRCTN 86184521) and of the 
High-STEACS pathway (NCT:03005158).26
ConClusIons
A novel high-sensitivity cardiac troponin I assay can safely 
identify two-thirds of patients with suspected acute coronary 
syndrome as low risk of myocardial infarction or cardiac death 
in the emergency department. Diagnostic pathways that harness 
the potential of high-sensitivity cardiac troponin testing by incor-
porating cardiac troponin concentrations within the reference 
range to risk stratify patients miss fewer events than pathways 
that rely on the 99th centile to rule out myocardial infarction.
Key messages
What is already known on this subject?
 ► High-sensitivity cardiac troponin assays can be applied as risk 
stratification tools in patients with suspected acute coronary 
syndrome.
 ► A recent individual patient-level data meta-analysis in 22 457 
patients demonstrated a high-sensitivity cardiac troponin I 
concentration <5 ng/L at presentation gave a high negative 
predictive value of 99.5% for myocardial infarction or cardiac 
death at 30 days.
What might this study add?
 ► This is the first report of a new commercially available 
high-sensitivity cardiac troponin I assay and evaluates its 
performance across three commonly used risk stratification 
pathways in clinical practice.
 ► We demonstrate pathways using low concentrations of 
cardiac troponin for risk stratification are safer and more 
effective than using the 99thcentile alone.
how might this impact on clinical practice?
 ► The evidence provided in this study will allow clinicians and 
biochemists to make informed decisions as to the optimal 
approach for risk stratification of patients with suspected 
acute coronary syndrome in their hospitals.
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